23 Sep Date September 23, 2024 Author TelaraPharma Tags Dr. Alberto Lázaro, The Cilastatin project Our CSO Dr. Alberto Lázaro publishes a Commentary in the Kidney International Journal about Cilastatin Our Co-Founder and CSO Dr. Alberto Lázaro has just published a Commentary in the Kidney International Journal, the official journ...
02 Aug Date August 2, 2024 Author TelaraPharma Tags Arch Biopartners, The Cilastatin project Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI) Cilastatin is parti...
27 Jun Date June 27, 2024 Author TelaraPharma Tags Arch Biopartners, The Cilastatin project Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product TORONTO, June 27, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and O...
01 Apr Date April 1, 2024 Author TelaraPharma Telara Pharma awarded €841.000 from Spanish government to characterize the mechanism of action of cilastatin to act as a preventive treatment in acute and chronic inflammatory indications Telara Pharma (Lead coordinator, Madrid, Spain), Fundación para la Investigación Biomédica del Hospital Gregorio Marañón (FIB...
05 Apr Date April 5, 2023 Author TelaraPharma Telara Pharma has been awarded a €325,000 non-refundable grant through the Spanish Ministry of Science and Innovation Neotec programme, managed by the Centre for the Development of Industrial Technology (CDTI). Neotec is a highly competitive programme that aims to foster technology and innovation for the development of companies based in S...
03 Jun Date June 3, 2021 Author TelaraPharma Tags Dr. Alberto Lázaro, Gregorio Marañon, IiSGM Telara Pharma awarded at the 8th IiSGM Research and Innovation Conference Alberto Lázaro, co-founder of Telara Pharma, wins the award for Best Communication with an innovation component for the presentat...
10 May Date May 10, 2021 Author TelaraPharma Tags Dr. Alberto Tejedor, GENESIS Biomed, Gregorio Marañon, The Cilastatin project The Gregorio Marañón Hospital creates Telara Pharma, a spin-off to market the drug that protects the kidney. • Cilastatin, is the nephroprotector discovered by the team led by Dr. Alberto Tejedor, who died of Covid-19 • The drug pre...
15 Apr Date April 15, 2021 Author TelaraPharma Tags Arch Biopartners, The Cilastatin project Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation No...
24 Nov Date November 24, 2020 Author TelaraPharma Tags Dr. Alberto Tejedor, Gregorio Marañon, renal injury Birth of Telara Pharma S.L. Telara Pharma S.L. has been created in Madrid (Spain), acquiring a license agreement with Gregorio Marañón Health Research insti...